Liver cancer risk study for hepatitis B patients with family history
Part of Cancer, Infections clinical trials.
This study tracks chronic hepatitis B patients who have a family history of liver cancer to understand their risk. It tests how well current antiviral treatments work in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had chronic hepatitis B for more than 6 months
- A parent, sibling, or grandparent has had liver cancer caused by hepatitis B
- You are 30 years or older
- You are currently taking an antiviral medication for hepatitis B (such as Entecavir, Tenofovir, or similar), or you are taking a combination with an interferon drug
- You are not pregnant or agree to a pregnancy test before starting (if you could become pregnant)
- You have never been diagnosed with liver cancer or another cancer, and you do not have any organ transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining peginterferon alpha-2b with a nucleoside analog can lower liver cancer risk in people with chronic hepatitis B who have a family history of liver cancer. It compares the combination therapy to nucleoside analog alone.
This study looks at your risk of developing liver cancer (hepatocellular carcinoma) if you have a liver condition such as NAFLD or a related disease. It aims to improve how doctors predict who might be at higher risk, so they can offer better monitoring and care.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
This study looks at how well different hepatitis B treatments help lower the risk of liver cancer. It's for people with chronic hepatitis B who are already using or starting certain antiviral or interferon therapies.
This early-stage trial tests whether a drug called pegylated interferon alpha-2β can help prevent hepatitis B-related liver cancer from coming back after surgery. The drug aims to boost your immune system to fight any remaining cancer cells.
This study looks at your risk of developing liver cancer if you have hepatitis B. It uses your medical history and test results to give you a better idea of your risk and help guide next steps.
Hear when a new HBV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.